Table 1. . Genome-wide association studies of antipsychotic response.
| Study | Year | Sample size | Source of study sample | Array platform | Ancestry | Medications (n) | Duration of illness | Period of observation | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Lavedan et al. | (2009) | 210 | Phase III drug trials | Affymetrix 500k | Mixed | Iloperidone | Not specified | 28 days | [9] |
| Ikeda et al. | (2010) | 108 | JPN_1, JPN_2, UK GWAS | Illumina Sentrix BeadChip | Japanese | Risperidone | First episode | 8 weeks | [10] |
| McClay et al. (CATIE) | (2011) | 738 | CATIE (PANSS) | Affymetrix 500k + custom 164k | Mixed | Olanzapine (173), perphenazine (119), quetiapine (160), risperidone (159), ziprasidone (90) | >1 year of schizophrenia diagnosis | 18 months | [11] |
| McClay et al. (CATIE) | (2011) | 738 | CATIE (cognition) | Affymetrix 500k + custom 164k | Mixed | Olanzapine (173), perphenazine (119), quetiapine (160), risperidone (159), ziprasidone (90) | >1 year of schizophrenia diagnosis | 18 months | [22] |
| Clark et al. (CATIE) | (2013) | 738 | CATIE (CGI-S and PGI) | Affymetrix 500k + custom 164k | Mixed | Olanzapine (173), perphenazine (119), quetiapine (160), risperidone (159), ziprasidone (90) | >1 year of schizophrenia diagnosis | 18 months | [12] |
| Drago et al. | (2014) | Discovery: 96; replication: 169 | Independent sample with replication in CATIE severely ill subset | Discovery: Illumina Human Hap 300 and Illumina Human 610-Quad, replication: Affymetrix 500k and custom 164k | Discovery: White, replication: mixed | Discovery: haloperidol; replication: mixed | Not specified | 1 month | [13] |
| Li et al. | (2014) | 174 | Previously collected prospective clinical trial | Illumina 610K Quad BeadChip® | Caucasian | Clozapine | Not specified | n/a (retrospective) | [23] |
| Stevenson et al. | (2016) | 86 | Independent sample | Affymetrix Genome-wide Human SNP array 6.0 | Mixed | Primarily risperidone | Yes | 6 weeks | [14] |
| Sacchetti et al. | (2016) | 86 | GEAR study | Affymetrix Human Mapping GeneChip 6.0 | Italian | Risperidone | Not specified | 2 weeks | [15] |
| Koga et al. | (2016) | 79 | Independent sample | Illumina HumanOmni2.5-8 BeadChip Kit | European | Mixed | >3 years of schizophrenia diagnosis | n/a (retrospective) | [25] |
| Koga et al. | (2017) | 84 | Independent sample | Illumina HumanOmni2.5-8 BeadChip Kit | European | Mixed | >3 years of schizophrenia diagnosis | n/a (retrospective) | [24] |
| Li et al. | (2017) | 1390 | Phase III drug trials | Human1M-Duov3 or PsychArray | European | Paliperidone | >1 year of schizophrenia diagnosis | 6–13 weeks | [16] |
| Li et al. | (2018) | 435 | Lurasidone Phase III trials | Illumina Omni5Exome-4v1 BeadChip | Mixed | Lurasidone | Not specified | 6 weeks | [18] |
| Yu et al. | (2018) | Discovery: 2413, replication: 1379 | Chinese Antipsychotics Pharmacogenomics Consortium | Illumina Human Omni ZhongHua-8 BeadChips | Han Chinese | Discovery: aripiprazole (397), haloperidol (192), olanzapine (425), perphenazine (193), quetiapine (386), risperidone (412), ziprasidone (408) Replication: aripiprazole (462), olanzapine (459), risperidone (458) |
Both first episode and relapsed patients | 6 weeks | [20] |
CATIE: Clinical antipsychotic trials of intervention effectiveness; PANSS: Positive and Negative Symptom Scale; CGI-S: Clinical Global Impression - Severity; PGI: Patient Global Improvement; GEAR: Genes and Early Antipsychotic Response; GWAS: Genome-wide association studies